Yury Mareev

@YMareev

cardiologist working in the field of heart failure and electrophysiology and also a researcher in Roberson Center of Biostatistics

Vrijeme pridruživanja: kolovoz 2019.
Rođen/a 1984.

Tweetovi

Blokirali ste korisnika/cu @YMareev

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @YMareev

  1. proslijedio/la je Tweet
    3. velj

    " Altman concluded that “We need less research, better research, and research done for the right reasons.” This is, in my opinion, the most important sentence ever written about medical research, but it fell on deaf ears." YES!

    Poništi
  2. proslijedio/la je Tweet
    2. velj

    When the attending teaches you a procedure & then you try it

    Poništi
  3. proslijedio/la je Tweet
    3. velj

    when your data just doesn’t support your hypothesis no matter what you do

    Poništi
  4. proslijedio/la je Tweet
    29. sij

    We were surprised to find 8.5% of eligible trials in our recent review update published in journals suspected to be . Potential problems: diluting credible literature, distorting evidence base with poor-quality, duplicated or fraudulent data 1/6

    Prikaži ovu nit
    Poništi
  5. proslijedio/la je Tweet
    30. sij

    Whole exome sequencing: ‘... 3710(53%) variants had no phenotypic correlation.’

    Prikaži ovu nit
    Poništi
  6. proslijedio/la je Tweet
    30. sij

    There's "precision medicine" and "rabbit hole medicine" This report represents the latter. How to collect an avg $8,000/person, do many tests to get lots of abnormal findings (for more testing) and "health outcome and benefits were not measured"

    Prikaži ovu nit
    Poništi
  7. proslijedio/la je Tweet
    31. sij

    discontinuation associated with a 33% increased risk of hospitalisation for a event in 75-year-old primary prevention patients: a French nationwide population-based cohort study

    Poništi
  8. proslijedio/la je Tweet
    30. sij

    9 of 10 people with first MI age < 60 have modifiable risk factors, many of them multiple

    Poništi
  9. proslijedio/la je Tweet

    Inferior vena cava (IVC) ultrasound in Acute : design & rationale of the CAVA‐ADHF‐DZHK10 trial An initial study to verify assessment of congestion through IVC evaluation

    Poništi
  10. proslijedio/la je Tweet
    30. sij

    My colleague and I wrote about this recently "High-dimensional data for a human being is an alluring yet unproven concept; "there is no validation..in the clinic"

    Prikaži ovu nit
    Poništi
  11. proslijedio/la je Tweet
    30. sij

    491 days after presented at conference, the trial is published! Many interesting things.... And finally, the ans to the question of whether this "saves lives" (thread)

    Prikaži ovu nit
    Poništi
  12. proslijedio/la je Tweet
    28. sij

    Don't you just love it when the phrase "this is hypothesis generating" is used to plaster over the use of wrong analytics/wrong data/wrong approach?

    Poništi
  13. proslijedio/la je Tweet
    27. sij

    Great news everyone! The competing events paper you’ve always wanted has finally been published!! If you do research on any outcome other than all-cause mortality then you should definitely clear some time to read this! 👇🏼👇🏼👇🏼

    Prikaži ovu nit
    Poništi
  14. proslijedio/la je Tweet
    28. sij

    All this talk of a new virus can be scary, but there are plenty of things regular people can do to help prevent or stop an outbreak. To see how you can help, check out my new post: “A regular person’s guide to outbreak preparedness” 👇🏼

    Poništi
  15. proslijedio/la je Tweet
    28. sij

    Wow, puts into perspective our therapeutic decisions in rich countries...

    Poništi
  16. proslijedio/la je Tweet
    25. sij

    A 15,000 person RCT of a controversial cancer screening, CT screening for lung cancer was presented on Sept 25th, 2018. People hailed it as "practicing changing" Now 487 days later... no published paper no preprint Acceptable?

    Prikaži ovu nit
    Poništi
  17. proslijedio/la je Tweet
    26. sij

    Randomized trials are expensive First, there is the cost of the RCT Then, there is all the lost earnings on drugs that don't work, but could have been approved via uncontrolled trials.

    Poništi
  18. proslijedio/la je Tweet
    27. sij

    Watch this AMAZING reminder of the classic changes of ↑K+ Your ability to recognize these will save lives!

    Prikaži ovu nit
    Poništi
  19. proslijedio/la je Tweet
    26. sij
    Odgovor korisnicima

    It’s the reason I’m trying to get my information from actual infectious disease experts rather than any old “Harvard trained epidemiologist” but I understand why the lay public could be easily tricked by such authority

    Poništi
  20. proslijedio/la je Tweet
    26. sij

    Is it time for us to pay more attention to tweeting papers? "Highly tweeted articles were 11x more likely to be highly cited" Don't just think impact factor - think "Twimpact factor"!

    Prikaži ovu nit
    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·